Notice of final decision to amend (or not amend) the current Poisons Standard - ACMS #38, Joint ACMS-ACCS #31, ACCS #34

This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulations 42ZCZS and 42ZCZX, this notice publishes the:

• A decision made by a delegate of the Secretary pursuant to regulations 42ZCZR and 42ZCZU;
• reasons for that final decision; and
• date of effect of the decision.

Final decision and reasons

We aim to provide documents in an accessible format. If you're having problems using this document, please contact medicines.scheduling@health.gov.au.

Contents

• 1 Notice of final decisions to amend (or not amend) the current Poisons Standard
• 2 Final decision in relation to psilocybine and MDMA
• 3 Final decisions on proposed amendments referred to the Advisory Committee on Medicines Scheduling (ACMS #38, June 2022)
  • 3.1 Final decision in relation to cetirizine
  • 3.2 Final decision in relation to budesonide
  • 3.3 Final decision in relation to apronal (allylisopropylacetylurea)
• 4 Final decisions on proposed amendments referred to the Advisory Committee on Medicines and Chemicals Scheduling in joint session (Joint ACMS-ACCS #31, June 2022)
  • 4.1 Final decision in relation to helional
  • 4.2 Final decision in relation to hydroxypinacolone retinoate (HPR)
  • 4.3 Final decision in relation to MDMA and MDA nomenclature
• 5 Final decisions on proposed amendments referred to the Advisory Committee on Chemicals Scheduling (ACCS #34, June 2022)
  • 5.1 Final decision in relation to dichloromethane
  • 5.2 Final decision in relation to ipflufenoquin
• 6 Amendments to the Poisons Standard in relation to New Chemical Entities (NCEs)
  • 6.1 Avacopan
  • 6.2 Deucravacitinib
  • 6.3 Edaravone
  • 6.4 Lenacapavir
  • 6.5 Patisiran
  • 6.6 Tirzepatide
• 7 Amendments to the Poisons Standard made as delegate-only decisions
  • 7.1 Final decision in relation to fenpropidin
  • 7.2 Final decision in relation to fluralaner